IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma ...Middle East

Confirmed overall response rate (ORR) of 45%, disease control rate (DCR) of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patients Based on FDA meeting, initiating Phase 2/3 registrational trial in Q2 2023 in First-Line HLA-A2 negative MUM, with median PFS as primary...

Hence then, the article about ideaya announces positive interim phase 2 data for darovasertib and crizotinib combination and successful fda type c meeting on registrational trial design for accelerated approval in first line metastatic uveal melanoma was published today ( Sunday 23/04/2023 - 04:01 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma )

Also on site :

• Russia-Ukraine war: List of key events, day 1,428
• Thrash Metal Icon Reveals Truth About Final Album of 43-Year-Old Band
• Christina Haack Stuns in Bikini With Boyfriend on Tropical Getaway